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Abstract
Introduction: B cells may play an important role in promoting immune activation in the rheumatoid synovium and can
produce prostaglandin E2 (PGE2) when activated. In its turn, PGE2 formed by cyclooxygenase (COX) and microsomal
prostaglandin E2 synthase 1 (MPGES1) contributes to the rheumatoid arthritis (RA) pathological process. Therapeutic
depletion of B cells results in important improvement in controlling disease activity in rheumatoid patients. Therefore we
investigated the expression of PGE2 pathway enzymes in RA B cells and evaluated the effects of B cell depleting therapy on
their expression in RA tissue.
Methods: B cells expressing MPGES1 and COX-2 were identified by flow cytometry in in vitro stimulated and control
mononuclear cells isolated from synovial fluid and peripheral blood of RA patients. Synovial biopsies were obtained from 24
RA patients before and at two consecutive time points after rituximab therapy. Expression of MPGES1, COX-1 and COX-2, as
well as interleukin (IL)-1b and IL-6, known inducers of MPGES1, was quantified in immunostained biopsy sections using
computerized image analysis.
Results: Expression of MPGES1 or COX-2 was significantly upregulated upon stimulation of B cells from blood and synovial
fluid while control cells displayed no detectable enzymes. In synovial biopsy sections, the expression of MPGES1, COX-1 or
COX-2 was resistant to rituximab therapy at 8 or 16 weeks after start of treatment. Furthermore expression of IL-1b in the
synovial tissue remained unchanged, while IL-6 tended to decrease after therapy.
Conclusions: Therapy with B cell depleting agents, although efficient in achieving good clinical and radiographic response
in RA patients, leaves important inflammatory pathways in the rheumatoid synovium essentially unaffected.
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease that
features persistent synovial inflammation and proliferation along
with infiltration of predominantly T lymphocytes, plasma cells and
macrophages. A central role for the B lymphocytes in the
pathogenesis of RA is supported by the presence of autoantibodies,
which are locally produced in the inflamed synovium and may
promote tissue inflammation and destruction by forming immune
complexes [1]. Moreover, a significant percentage of RA patients
display ectopic lymphoid structures in the synovial membrane
[2,3] that could sustain T and B cell interaction [4]. Finally,
effector B cells produce cytokines and other immunological
mediators [5] thereby promoting the extent and direction of
immune responses [6]. The observation that therapeutic B cell
depletions using rituximab treatment disrupts synovial lymphoid
neogenesis and decreases macrophages infiltration supports the
notion that B cells orchestrate synovial inflammation in RA [7].
In the rheumatoid joint, the synovial fluid (SF) contains a variety
of cytokines, chemokines, growth factors and lipid-derived
mediators, which potentially mediate B cells effector functions.
Of the prostaglandins, high levels are reached by prostaglandin E2,
(PGE2) which plays a prominent role in the rheumatoid
pathogenic process by promoting tissue damaging and autoim-
munity [8,9]. Microsomal prostaglandin E2 synthase (MPGES) 1
catalyses its formation from cyclooxygenase-derived PGH2 and is
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of RA patients [10]. MPGES1 is mostly found in fibroblast-like
synoviocytes (FLS) and macrophages. Cyclooxygenase (COX)
enzymes known as COX-1 and COX-2 are also widely expressed
in the inflamed synovium. COX-1 is present in intimal lining layer
and synovial sublining mononuclear cells and FLS [10,11]. COX-
2 has a similar localization, but is also highly expressed by
endothelial cells [11]. Furthermore, whereas COX-1 expression is
independent of the inflammatory status in the joint tissue, COX-2
is markedly upregulated at sites of inflammation [12]. Proin-
flammatory cytokines present in the rheumatic milieu, such as
tumor necrosis factor (TNF), interleukin (IL) 1b [13] and IL-6 [14]
are prominent inducers of MPGES1. In turn, by interacting with
FLS, PGE2 promotes release of IL-6 [15] and matrix metallopro-
teinase-1 [16], thereby further sustaining a pathogenic circle.
COX-2 derived PGE2 also plays a central role in the humoral
responses, since blocking this pathway substantially decreases
antibody production [17]. PGE2 regulates B cell proliferation and
activation [18] as well as survival [19]. This implies a possible role
for PGE2 as a mediator of B cell immune responses in RA. To
investigate this hypothesis, we studied the expression of PGE2-
related enzymes in SF and peripheral blood (PB)-derived B cells of
RA patients. Furthermore, we hypothesised that depleting B cells
could change synovial immune interactions, reduce cytokine levels
and decrease disease activity in the inflamed joint. These effects
can in turn affect the PGE2 biosynthetic pathway and further
contribute to decline local inflammation and clinical benefit. In
this sense, it has been reported that B cells are essential in
sustaining PGE2 production by lung macrophages [20]. Therefore,
we analysed the in vivo effects of B cell depletion by examination of
serial synovial tissue biopsies obtained before and at two
consecutive points after rituximab treatment.
Materials and Methods
Cell preparation and flow cytometric analysis
SF and PB mononuclear cells (MC) from 10 RA patients were
collected by gradient centrifugation using Ficoll-Paque (Phar-
macia, Uppsala, Sweden) and stored in liquid nitrogen until
assayed. Cells were cultured in RPMI medium containing
2 mM glutamine, 100 IU/mL penicillin, 100 IU/ml strepto-
mycin and 5% human serum, at 37uCi nah u m i d i f i e d
atmosphere containing 5% CO2. To activate B cells, Staphylo-
coccus aureus Cowan strain I and pokeweed mitogen (both from
Sigma-Aldrich, Sweden) were added to the cultures at a final
concentration of 10 mg/ml and 0.1 mg/ml, respectively, and
cells were incubated for 16 hours. Detection of intracellular
enzymes by flow cytometry was performed both in incubated
cells and in unstimulated cells before culture, by using anti-
MPGES1 and COX-2 antibodies according to previously
described protocol [10]. Briefly, SFMC or PBMC were washed
in 5% human serum, followed by staining of surface marker
with anti-CD19-PerCP mouse monoclonal antibody (Becton
Dickinson, San Jose, CA). Subsequently cells were fixed in 4%
paraformaldehyde and incubated with rabbit polyclonal antise-
rum raised against MPGES1 [21] and mouse monoclonal anti-
COX-2 (CX229; Cayman Chemical, Ann Harbor, MI)
antibodies in saponin containing phosphate buffer, followed by
addition of secondary FITC-coupled anti-rabbit or anti-mouse
antibodies. B cells were identified based on scatter properties
and CD19 expression and were then analyzed for expression of
MPGES1 and COX-2. Due to technical issues in using COX-1
antibody for flow cytometry, we did not further pursue analysis
of COX-1 in these cells.
Patients and treatment protocol
Twenty-four patients were included from a study on the
mechanism of action of rituximab in RA that was reported
previously [7]. Patients had active RA (Disease Activity Score
evaluated in 28 joints (DAS28$3.2) [22] despite previous
treatment with combination(s) of disease-modifying antirheumatic
drugs (DMARDs) and/or TNF-blocking agents. During the study
they were treated with stable dosages of methotrexate; stable
treatment with non-steroidal anti-inflammatory drugs (NSAIDs)
and prednisone (when taken orally in a dosage up to 10 milligrams)
was allowed. The study was approved by the local Medical Ethical
Committee of the Academic Medical Center/University of
Amsterdam and all patients gave their written consent before
participation in the study.
Treatment and clinical evaluation
The patients were treated with two infusions of 1,000 mg
rituximab (Roche, Woerden, The Netherlands) at day 1 and day
14. Methylprednisolon premedication was omitted to be able to
study the specific effects of rituximab. The clinical baseline
characteristics of the cohort were described previously [7]. The
DAS28 was measured monthly after treatment until week 24.
Response to treatment was considered according to the European
League Against Rheumatism (EULAR) response criteria [23].
Responders were defined as those patients that had a good or
moderate response during at least two consecutive study visits
according to EULAR criteria.
Synovial biopsy and immunohistochemistry
Synovial tissue was obtained using arthroscopy- guided synovial
biopsy as described previously [24]. Biopsies were collected from
the same affected joint before treatment as well as 4 weeks and 16
weeks after initiation of therapy. Immunohistochemical staining
was performed on serial cryosections using MPGES1 antiserum,
rabbit polyclonal anti-COX-1 (Cayman Chemical), mouse mono-
clonal anti-COX-2 (Cayman Chemical) antibodies, mouse anti-
human CD20 (L26; DakoCytomation, Glostrup, Denmark),
mouse anti-human IL-6 (B-E8; Millipore Chemicon, Billerica,
MA) and mouse anti-human IL-1 (2D8; Immunokontact,
Abingdon, United Kingdom). The procedure has been published
earlier [25]. For surface marker staining we used the following
mouse monoclonal antibodies: anti-CD22 (CLB-B-Ly; Central
laboratory of The Netherlands Red Cross Blood Transfusion
Centre, Amsterdam) for B cells, anti-CD3 (SK7; Becton
Dickinson) for T cells, anti-CD138 (B-B4; Immunotech, Marseille,
France) for plasma cells and anti-CD68 (EBM11; Dako, Glostrup,
Denmark) for macrophages, as previously described [7]. Out of
the 24 patients included, we have analyzed biopsy sections at all
three time points in 16 patients. Due to synovial sections of
insufficient quality, samples from one patient taken at week 4 and
from two patients at week 16 were not included in the analysis.
Additionally two patients had un-assessable tissue sections in the
baseline biopsy. Three patients where we could only assess biopsy
at one time point were excluded from the analysis.
Stained sections were quantitatively evaluated by computer-
assisted image analysis on a Polyvar II microscope and expressed
as percentage of positive staining versus total counterstained
area. IL-1 and IL-6 staining was quantified as the integrated
optical density, using a Leica DM-RXA light microscope
[26]. Double immunofluorescence was performed on SFMC
cultured on chamber slides with or without activation stimuli,
using rabbit MPGES1 antiserum and a mixture of mouse
monoclonal anti-CD19 and anti-CD20 antibodies (Dako Cyto-
mation), using a protocol published earlier [21]. For immunoflu-
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samples were incubated with primary antiserum against
MPGES1 and mouse monoclonal antibody against CD55
(Serotec, Oxford, UK), CD20 (Dako Cytomation) and CD138
(B-A38; Diaclone, Besancon, France), followed by addition of
anti-rabbit Alexa 594 and anti-mouse Alexa 488 conjugated
mouse monoclonal antibodies (both from Molecular Probes,
Eugene, Oregon).
Statistical analysis
For comparison of paired synovial biopsy samples, Wilcoxon-
matched paired test for nonparametric data was used. Statistical
analysis of flow cytometry data was performed using Mann-
Whitney test or Wilcoxon test for paired samples and Bonferroni
corrections were applied for multiple comparisons. Spearman rank
correlation test for non-parametrical samples was applied for
correlation analysis.
Results
Activated B cells from synovial fluid display a higher
expression of MPGES1 and COX2 enzymes compared to
peripheral blood
RA B cells originating from SF or PB expressed minimal levels
of MPGES1 or COX-2 after incubation without stimuli, but could
significantly upregulate their expression after in vitro stimulation
with Staphylococcus aureus Cowan strain I and pokeweed mitogen
(Fig. 1 A, B). The expression was significantly higher in the B cell
population from SF compared to PB (p=0.002). Unstimulated B
cells displayed no COX-2 expression before culture either in SF or
PB (data not shown), while low MPGES1 was detected in B cells in
some of the SF samples (median 0, range 0-10.2%). Confirming
our flow cytometric data, we detected by immunofluorescence
MPGES1 positive B cells in activated RA SFMC (Fig. 1D), but not
in unstimulated cells (Fig. 1C).
Figure 1. Expression of MPGES1 and COX-2 in synovial fluid (SF) and peripheral blood (PB)-derived B cells. In rheumatoid arthritis
patients, SF B cells stimulated in vitro expressed higher levels of MPGES1 and COX-2 than PB B cells. A, Percentage of B cells that are MPGES1 positive
in unstimulated and stimulated SFMC and PBMC. B, Percentage of B cells that are COX-2 positive in unstimulated and stimulated SFMC and PBMC.
** = P,0.01, *** = P,0.001. C, D Immunofluorescence staining of unstimulated (C) and activated (D) RA synovial fluid cells showing CD19 positive B
cells (red), MPGES1 positive cells (green) and double stained cells (yellow). Original magnification 250x.
doi:10.1371/journal.pone.0016378.g001
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rheumatoid synovium
Both chromogenic and double fluorescence staining of synovial
biopsies from several RA patients revealed that MPGES1 positive
cells and B cells were not co-localized in the same tissue areas. As
illustrated in Fig. 2, CD20 positive B cells and CD138 plasma cells
have different areas of distribution compared to MPGES1
expressing cells, with virtually no overlapping. Indeed, B cells
mostly accumulate inside lymphoid structures in synovial sections
that display follicular synovitis, while MPGES1 positive cells can be
found in intimal lining layer and synovial sublining regions, in
agreement with our previous study [21]. Also, in RA biopsies not
showingectopiclymphoid neogenesis, the pattern ofdetected B cells
is variable, from scattered isolated cells to extremely scarce (data not
shown), whereas strong MPGES1 expression is virtually the rule.
Expression of COX enzymes was detected in intimal and
sublining macrophages as well as in FLS (Fig. 2 B, C), as previously
described [10]. In addition, cells surrounding vessels were
positively stained for COX-2, while inflammatory lymphoid
aggregates did not display any specific COX-2 expression. In
some patients we could however detect COX-1 expressing cells
within the lymphoid inflammatory infiltrates, possibly coinciding
with localization of CD20 positive B cells.
Clinical response to rituximab treatment
The DAS28 did not decrease yet at 4 weeks, but there was a
statistically significant decrease in DAS28 from week 8 with a
maximum mean decrease at week 20 (compared to baseline: mean
(SD) decrease of 0.96 (1.1) at week 8 and 1.85 (1.4) at week 20;
both p,0.001). Of the 24 patients studied, 4 patients had a good
response according to EULAR response criteria and 15 patients
had a moderate response, while 5 patients did not fulfil response
criteria [7].
B cell depletion therapy has limited effects on expression
of MPGES1 and COX enzymes in RA synovium
Analysis of MPGES1, COX-1 and COX-2 in synovial tissue
showed no statistically significant change in their expression at 4
Figure 2. MPGES1 is not expressed in B cell-rich areas in RA synovium. Frozen sections of synovial tissue showing diaminobenzidine
(brown) staining of MPGES1 (A), COX-2 (B), COX-1 (C) and CD20 B cells (D), CD138 plasma cells (E) (hematoxiline counterstained). Insets represent
higher power of image A and D. Original magnification 80x and 200x (insets). (F) and (G) Immunofluorescence pictures of double stained MPGES1
(red) and CD20+ B cells (F) and CD138+ plasma cells (G) (green). Magnification 400x.
doi:10.1371/journal.pone.0016378.g002
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(Fig. 3).
On an individual response level, 7 patients showed an initial
decrease in MPGES1 positive staining at 4 weeks, followed by a
subsequent increase at 16 weeks, while 4 patients followed a
different pattern with enhanced expression at 4 weeks and a
decrease thereafter. In most of the patients we observed a large
variability in the synovial MPGES1 response to rituximab between
the different time points. A trend towards decreased COX-2
expression at 4 weeks was observed, albeit non-significant
(P=0.09) which was similarly maintained at 16 weeks (P=0.1).
COX-1 expression displayed however variable changes over time
in individual patients, with no identifiable trend. Analysis of
subgroups of patients not taking NSAID or GC medication
showed no significant differences between groups and no
consistent change in enzyme expression over time.
Next, we investigated if the synovial expression of these enzymes
followed a specific pattern in responders versus non-responder
patients and if the change in enzyme expression at 4 or 16 weeks is
correlated with the change in inflammatory cell numbers in the
tissue. As shown in Fig. 4, no specific response pattern could be
observed in either of the groups, and no statistical significant
difference was detected between responders and non-responders at
baseline or at any of the later time points studied. Furthermore, the
change in cell surface marker expression for B cells, T cells, plasma
cells and lining and sublining macrophages did not correlate with
the difference in enzyme expression at 4 weeks or 16 weeks
following therapy start (data not shown). Thus the variability in the
synovial enzyme expression was in our study not related to the
clinical outcome or the inflammatory cell load in the synovial tissue.
Subsequently we analyzed the cells expressing MPGES1 before
and after treatment and showed that the enzyme is still present in
CD55 positive FLS 16 weeks after rituximab treatment start
(Fig. 5).
B cell depletion has limited effect on MPGES1-inducing
cytokines
The absent effect of rituximab on MPGES1 expression suggests
a similar limited effect on the expression of MPGES1 inducing
cytokines. Therefore we analyzed the change in synovial IL-1b
and IL-6 expression after treatment. Before treatment IL-6 and
IL-1b were present on cellular membranes and diffusely in the
synovial extracellular matrix. Rituximab treatment induced a
trend towards a decrease in IL-6 (P=0.062) expression at week 16
but not in IL-1b (P=0.12) (Fig. 6).
Discussion
In this study we demonstrate that MPGES1 and COX-2
enzymes are upregulated in SF B cells upon activation while
synovial tissue B cells do not express these enzymes. Furthermore,
after B cell depletion therapy MPGES1, COX-1 and COX-2
levels in synovium of RA patients are essentially unaffected 4
weeks or 16 weeks after therapy despite clinical improvement in
the majority of the studied patients. Also IL-1b and IL-6, strong
inducers of MPGES1, did not change significantly.
Figure 3. Minimal influence of rituximab treatment on expression of MPGES1, COX-1 and COX-2 in synovial tissue.
Immunohistochemical staining of frozen biopsy sections from rheumatoid arthritis patients shows diaminobenzidine staining (brown) of MPGES1
(A–C), COX-2 (E-G) and COX-1 (I–K) before treatment, 4 weeks and 16 weeks after treatment (hematoxiline counterstained). Graphs depict image
analysis of MPGES1 (D), COX-2 (H) and COX-1 (L) expression in stained sections from patients’ biopsies at the different time points. Original
magnification 150x.
doi:10.1371/journal.pone.0016378.g003
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cells of healthy volunteers [27]. We found the same effect in SF
and PB B cells from RA patients. In the synovial tissue we
observed MPGES1 expression in intimal macrophages, scattered
sublining macrophages and FLS. A similar distribution was
observed for COX-2 with additionally positive staining around
vessels. This is in line with a previous study describing MPGES1
localization in synovial tissue [21]. Indeed cells expressing
MPGES1 in the synovium are mostly fibroblasts and macrophag-
es. Also, we showed here that in RA synovial tissue MPGES1 is
not present in B cell-rich areas such as the lymphoid aggregates.
Despite failing to detect MPGES1 positive B cells in the
rheumatoid tissue, we showed that SF and PB B cells from RA
patients are able of upregulating MPGES1 and COX-2 upon in
vitro activation while unstimulated B cells do not readily express
these enzymes. These differences between in vitro activated SF B
cells and synovial tissue B cells suggest that activation signals that
are required to upregulate MPGES1 in B cells are not present in
RA synovium. Moreover, we report here that activated B cells
from SF have a higher expression level of MPGES1 and COX-2
than those from PB, suggesting that the local synovial compart-
ment has a different repertoire of immune cells or a particular
Figure 4. The expression of the PGE2 biosynthetic enzymes does not differ between responder and non-responder patients. Graphs
display immunohistochemical analysis of stained biopsy sections for MPGES1, COX-1 and COX-2 expression in individual responder/non-responder
patients at baseline and at 4 weeks and 16 weeks after initiation of rituximab treatment.
doi:10.1371/journal.pone.0016378.g004
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memory or naive B cells may vary between PB and SF with some
phenotypes being prone to express these enzymes more than
others. As such, the difference in enzyme expression that we
detected may simply reflect the different abilities of the B cell
subsets to respond to activation stimuli.
We showed that B cell depleting therapy exerts little effect on
the PGE2 pathway enzymes, in agreement with our observation
that B cells do not express these enzymes in the synovial tissue.
However, B cells are important contributors to the inflammatory
milieu in RA also by virtue of their capacity to activate T cells and
secrete cytokines [28]. Since COX-2 and MPGES1 expression is
inflammation-induced, a reduction of the B cell load in the
rheumatoid tissue could in theory be followed by a decrease in
antibody and cytokine formation and a reduced interaction with
other immune cells, leading to a decrease in their activity and
infiltration. Indeed a recent study of the same cohort showed that
rituximab induces a decrease in the number of synovial T cells,
macrophages and more heterogeneously, plasma cells [7]. In line
with these changes, the inducible prostaglandin synthesis could
have been affected. Of importance, our study showed that
although achieving clinical improvement in a large percentage of
the patients studied, rituximab did not change the local expression
of MPGES1 and COX. Moreover, the variation in enzyme
expression between the different time points did not reflect the
change in synovial inflammatory cell populations, such as B cells,
T cells, plasma cells and macrophages. In line, we found no clear
cut decrease in the local expression of IL-1b and IL-6, even
though these are produced by B cells, T cells and macrophages.
Similarly, we have previously reported that anti-TNF agents do
not suppress expression of MPGES1 or COX-2 in the rheumatoid
synovium [10]. Taken together, these data indicate that important
inflammatory pathways are relatively unaffected despite rituximab
mediated B-cell depletion and indirect decrease in other
inflammatory cells. Possibly, rituximab exerts relatively little
effects on activation of the more resident cell populations in the
Figure 5. MPGES1 expression in synovial lining fibroblasts before and 16 weeks after initiation of rituximab therapy. Double
immunofluorescence pictures show the presence of MPGES1 (red) expression in CD55 positive fibroblasts (green) in the rheumatoid tissue before
rituximab initiation (A) and 16 weeks later (B). Original magnification 500x. Arrows point to double stained cells.
doi:10.1371/journal.pone.0016378.g005
Figure 6. Rituximab treatment exerts limited effects on the synovial tissue expression of IL-1b and IL-6. Graphs show image analysis of
positive stained sections for (A) IL-1b and (B) IL-6 before and at consecutive time points after initiation of rituximab therapy. At week 16 a trend
towards decrease occurred in IL-6 but not in IL-1b.
doi:10.1371/journal.pone.0016378.g006
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macrophages. It should be noted that we cannot completely
exclude the possibility of a delayed effect of rituximab on
MPGES1 and COX enzymes that may become evident after 16
weeks of treatment.
Despite almost complete B cell depletion in the periphery,
persistence of synovial B cells is seen in a subset of patients [29],
which also correlates with infiltration with other inflammatory
cells [7]. While the decrease in synovial plasma cells can predict
the response to B cell depleting agents [7], persistence of plasma
cell infiltration is associated with residual synovial inflammation
[30]. It is hypothesized that the synovial milieu harbours molecules
able to rescue B cells and promote their survival [29]. In this sense,
it is worth mentioning the ability of PGE2 to promote survival
pathways and support viability of B cells [31]. Thus the persistence
of an active PGE2 pathway despite rituximab treatment may
contribute to later relapse.
The majority of the patients included in this study received
concomitant medication with NSAIDs, which can decrease the
formation of PGE2 in synovial fluid, albeit not completely, and
even affect COX-2 production, as seen in ostheoarthritis [32].
Despite representing an inherent confounding factor in such
clinical studies, NSAIDs do not alter MPGES1 expression. In
addition, once this medication is discontinued, COX activity may
resume and account, together with MPGES1, for PGE2
production.
In some patients it is possible that the remaining synovial B cells
may enhance PGE2 pathway in local fibroblasts and macrophages.
Furthermore, it is noteworthy that PGE2 is capable of upregulating
its own formation in an autocrine manner [33,34], and thus local
MPGES1 expressing cells can provide a positive feedback. Here
we showed that expression of PGE2 related enzymes is most likely
not a simple result of the local number of inflammatory cells, but
of the interplay of mediators.
In conclusion, we demonstrated in this study that rituximab
therapy has minimal influence on synovial expression of enzymes
involved in the PGE2 pathway, despite clinical response in most
RA patients. Furthermore, recent reports have demonstrated that
optimal antibody production by B cells needs COX-2-derived
PGE2 [17], implying that blocking this pathway may possibly lead
to reduced antibody formation in synovial tissue and thus less joint
damage. Together, these data may provide one explanation for the
fact that rituximab treatment, similar to TNF blockade, does not
induce complete remission in the majority of the RA patients and
suggest that blocking the PGE2 pathway by targeting MPGES1
may lead to novel therapeutical strategies and complement current
anti-rheumatic therapy by providing additional benefit in
controlling the inflammatory process in the rheumatoid joint.
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